Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport

No abstract is available for this paper.

• Publication year

  2013

• Venue

  FEBS Letters

• Publication date

  2013-05-02

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.febslet.2013.02.027PMID 23499248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

  2012cited by this paper
• [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

  2012cited by this paper
• Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

  2012influential reference
• Gene Inactivation of PCSK9 Reduces Atherosclerosis in Mice

  2012cited by this paper
• The ABC transporters in lipid flux and atherosclerosis.

  2011influential reference
• PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway

  2011cited by this paper
• Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.

  2011cited by this paper
• Clinical aspects of PCSK9.

  2011cited by this paper
• Effects of PCSK9 siRNA on CD36,SR-A1 and SR-B1 expression in THP-1 derived macrophages

  2011cited by this paper
• Future Therapeutic Directions in Reverse Cholesterol Transport

  2010cited by this paper
• Mechanisms of LDL oxidation.

  2010cited by this paper
• Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control

  2010cited by this paper
• Effects of pcsk9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL

  2009cited by this paper
• Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

  2009cited by this paper
• Abstract: P174 NARC-1/PCSK9 IS EXPRESSED IN ATHEROSCLEROTIC LESION OF NEW ZEALAND RABBIT

  2009cited by this paper
• PCSK9 as a therapeutic target of dyslipidemia

  2009cited by this paper
• Effects of pcsk9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL*: Effects of pcsk9 siRNA on THP-1 Derived Macrophages Apoptosis Induced by oxLDL*

  2009cited by this paper
• The LDL receptor.

  2009cited by this paper
• Effects of LDL and oxLDL on Expression of PCSK9 and LDLR in THP-1 Macrophages

  2008cited by this paper
• Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

  2008cited by this paper
• Genetic Deletion of Low Density Lipoprotein Receptor Impairs Sterol-induced Mouse Macrophage ABCA1 Expression

  2008cited by this paper
• HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

  2008cited by this paper
• The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

  2008cited by this paper
• Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

  2008cited by this paper
• Inhibition of squalene synthase upregulates PCSK9 expression in rat liver.

  2008cited by this paper
• Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update

  2007cited by this paper
• Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport

  2007cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M400396-JLR200

  2005cited by this paper
• Heparan Sulfate Proteoglycans Participate in Hepatic Lipaseand Apolipoprotein E-mediated Binding and Uptake of Plasma Lipoproteins, Including High Density Lipoproteins*

  1997cited by this paper
• Native and Modified Low Density Lipoproteins Increase the Functional Expression of the Macrophage Class B Scavenger Receptor, CD36*

  1997influential reference
• Macrophage oxidative modification of low density lipoprotein occurs independently of its binding to the low density lipoprotein receptor.

  1996cited by this paper
• Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver, and intestine.

  1989cited by this paper

• Male-specific amelioration of lipid metabolism by edible insect Locusta migratoria in rats fed a cholesterol diet: Ingredients, mechanisms, and sex-differences

  2025cites this paper
• PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase

  2024cites this paper
• Burdock fructooligosaccharide ameliorates the hypercholesterolemia and vascular inflammation in mice by regulating cholesterol homeostasis and anti-inflammatory properties

  2023cites this paper
• Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics

  2023cites this paper
• Molecular and cellular biology of PCSK9: impact on glucose homeostasis

  2022cites this paper
• Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome

  2022influential citation
• Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9

  2020cites this paper
• Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department

  2020cites this paper
• Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction

  2019cites this paper
• PCSK9 inhibition and inflammation: A narrative review.

  2019cites this paper
• PCSK9 and inflammation: Role of shear stress, pro-inflammatory cytokines and LOX-1 4.

  2019cites this paper
• Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?

  2018cites this paper
• PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages

  2018cites this paper
• Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies.

  2018cites this paper
• Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention

  2018cites this paper
• PCSK9 and infection: A potentially useful or dangerous association?

  2018cites this paper
• From lipid locus to drug target through human genomics.

  2018cites this paper
• Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.

  2018cites this paper
• PCSK9 targets important for lipid metabolism

  2017cites this paper
• PCSK9 at the crossroad of cholesterol metabolism and immune function during infections

  2017cites this paper
• Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism

  2017cites this paper
• Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.

  2017cites this paper
• PCSK9 Inhibition in Acute Myocardial Infarction: A Novel Opportunity

  2016cites this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome

  2016cites this paper
• Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)

  2015cites this paper
• Effects of lipoprotein apheresis on PCSK9 levels.

  2015cites this paper
• Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.

  2015cites this paper
• PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

  2014cites this paper
• Perspektiven zu cholesterinwirksamer Behandlung 2014

  2014cites this paper